市場調查報告書
商品編碼
928280

代謝性酸中毒 - 流行病學預測 2030年

Metabolic Acidosis - Epidemiology Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的代謝性酸中毒市場調查,疾病概要,主要7個國家的市場趨勢,流行病學的預測,患病數、診斷數的變化與預測,未滿足需求等資訊彙整。

目錄

第1章 主要洞察

第2章 代謝性酸中毒概要

第3章 SWOT分析

第4章 市場概要

第5章 代謝性酸中毒:疾病的背景和概要

  • 簡介
  • 徵兆、症狀
  • 病因
  • 代謝性酸中毒對腎臟的影響

第6章 診斷

  • 代謝性酸中毒的管理

第7章 流行病學和患者人口

  • 主要調查結果
  • 假設和根據
  • 流行病學預測

第8章 美國的流行病學

  • 總患病數
  • 總診斷數
  • 治療完畢患者數

第9章 歐洲、日本的流行病學

  • 德國
    • 總患病數
    • 總診斷數
    • 已治療患者數
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第10章 未滿足需求

第11章 病人旅程

第12章 關鍵意見領袖的意見

第13章 附錄

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

目錄
Product Code: DIEI0684

Overview

DelveInsight's 'Metabolic Acidosis- Epidemiology Forecast2030' report delivers an in-depth understanding of the disease, along with historical and forecasted Metabolic Acidosis epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.

Metabolic Acidosis Understanding

Acid-base disorders, comprising of metabolic acidosis, are disturbances in the homeostasis of plasma acidity. Distinct acidosis can be characterized by a process that increases serum hydrogen-ion concentration. The term acidemia is used to define the total acid-base status of the serum pH. For example, a patient can have multiple acidosis contributing to a net acidemia. It is categorized, based upon its origin-as either a respiratory acidosis that involves changes in CO2 level, or metabolic acidosis, which is influenced by bicarbonate (HCO3).

Metabolic acidosis is defined by an increase in the hydrogen-ion concentration in the systemic circulation, which results in a serum HCO3 <24 mEq/L. It is not a benign condition and shows an underlying disorder that needs to be corrected to minimize morbidity and mortality. The many etiologies of metabolic acidosis are classified mainly into four mechanisms: acid ingestion, increased production of acid, decreased excretion of acid, and renal or gastrointestinal (GI) bicarbonate losses.

Metabolic acidosis can be acute or chronic. Acute metabolic acidosis is comparatively more common among severely ill patients than chronic metabolic acidosis. The frequency of chronic metabolic acidosis might increase with the expected rise in chronic kidney disease (CKD) in the geriatric population. Metabolic acidosis, acute or chronic, can have adverse effects on cellular function and can contribute to increased morbidity and mortality.

Epidemiology Perspective by DelveInsight

Metabolic acidosis epidemiology segment provides insights about historical and current metabolic acidosis patient pool and forecasted trends for 10 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Metabolic Acidosis Detailed Epidemiology Segmentation

The total prevalent cases of metabolic acidosis patients were found to be more in males than in females in 10EM during the study period 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Metabolic Acidosis epidemiology segmented as Total Prevalent Population of CKD patients, Total Prevalent Population of Metabolic Acidosis in CKD patients, Gender-Specific Diagnosed Population of Metabolic Acidosis, Total Diagnosed Population of Metabolic Acidosis, and Total Treated Population of Metabolic Acidosis in 10EM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, Brazil, China, and Mexico from 2017 to 2030.

Country Wise Metabolic Acidosis Epidemiology

The epidemiology segment also provides the metabolic acidosis epidemiology data and key findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.

  • As per the DelveInsight estimates, the total prevalent cases of CKD patients in 10 EM were 263,018,799 in 2017, which are expected to reach a significantly high number by 2030.
  • As per the DelveInsight analysis, the total prevalent cases of metabolic acidosis in China was found to be 8,881,796 in 2017, which are expected to reach a significantly high number by 2030.
  • As per the DelveInsight analysis, in the year 2017, the gender-specific diagnosed cases of metabolic acidosis in Germany were 194,037 in males and 158,757 in females, which are expected to reach a significantly high number by 2030.

Scope of the Report

  • The Metabolic Acidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Metabolic Acidosis Report and Model provide an overview of the risk factors and global trends of Metabolic Acidosis in the 10 emerging markets the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.
  • The report provides insight about the historical and forecasted patient pool of metabolic acidosis in the 10 emerging markets the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.
  • The report helps to recognize the growth opportunities in the 10EM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of metabolic acidosis.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Prevalent Population of CKD patients in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Prevalent Population of Metabolic Acidosis in CKD patients in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Gender-Specific Diagnosed Population of Metabolic Acidosis in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Diagnosed Population of Metabolic Acidosis in 10EM.
  • The report provides the segmentation of the metabolic acidosis epidemiology by Total Treated Population of Metabolic Acidosis in 10EM.

Report Highlights

  • 12-Year Plus Forecast of Metabolic Acidosis epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of Metabolic Acidosis
  • Prevalent Cases according to segmentation: Gender-specific
  • Diagnosed cases of Metabolic Acidosis
  • Treated cases of Metabolic Acidosis

KOL-Views

We interview KOLs and SME's for their opinion through primary research to fill the data gaps and validate our secondary research; this helps to understand the total patient population and current diagnosis pattern. It will support the clients in identifying the epidemiology scenario of the indication.

Key Questions Answered

  • What will be the growth opportunities in the 10EM with respect to the patient population pertaining to Metabolic Acidosis?
  • What are the key findings pertaining to the Metabolic Acidosis epidemiology across 10EM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Metabolic Acidosis across the 10EM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 10EM during the study period (2017-2030)?
  • What is the disease risk, burden and unmet needs of Metabolic Acidosis?
  • Which diagnosis strategy is followed and suggested by the healthcare experts?

Reasons to buy

The Metabolic Acidosis Epidemiology report will allow the user to:-

  • Develop business strategies by understanding the trends shaping and driving the Global Metabolic Acidosis Epidemiology.
  • Quantify patient populations in the Global Metabolic Acidosis Epidemiology to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for the regions covered.
  • Understand the magnitude of Metabolic Acidosis population by its severity.
  • The Metabolic Acidosis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Metabolic Acidosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 12-year plus forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • Brazil
  • China
  • Mexico

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Metabolic Acidosis

3. SWOT Analysis of Metabolic Acidosis

4. Metabolic Acidosis: Market Overview at a Glance

5. Metabolic acidosis: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Signs and Symptoms
  • 5.3. Pathogenesis
  • 5.4. Etiology
  • 5.5. Effects of metabolic acidosis on the kidney

6. Diagnosis

  • 6.1. Management of metabolic acidosis in CKD

7. Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 10EM
  • 7.3. Epidemiology Scenario: 10EM
    • 7.3.1. Total Prevalence of CKD patients in the 10EM
    • 7.3.2. Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM
    • 7.3.3. Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM
    • 7.3.4. Total Diagnosed Population of Metabolic Acidosis in the 10EM
    • 7.3.5. Total Treated Population of Metabolic Acidosis in the 10EM

8. The United States Epidemiology

  • 8.1. Total Prevalent Population of Metabolic Acidosis in the United States
  • 8.2. Total Diagnosed Population of Metabolic Acidosis in the United States
  • 8.3. Total Treated Population of Metabolic Acidosis in the United States

9. EU-5 Epidemiology

  • 9.1. Germany
    • 9.1.1. Total Prevalent Population of Metabolic Acidosis in Germany
    • 9.1.2. Total Diagnosed Population of Metabolic Acidosis in Germany
    • 9.1.3. Total Treated Population of Metabolic Acidosis in Germany
  • 9.2. France
    • 9.2.1. Total Prevalent Population of Metabolic Acidosis in France
    • 9.2.2. Total Diagnosed Population of Metabolic Acidosis in France
    • 9.2.3. Total Treated Population of Metabolic Acidosis in France
  • 9.3. Italy
    • 9.3.1. Total Prevalent Population of Metabolic Acidosis in Italy
    • 9.3.2. Total Diagnosed Population of Metabolic Acidosis in Italy
    • 9.3.3. Total Treated Population of Metabolic Acidosis in Italy
  • 9.4. Spain
    • 9.4.1. Total Prevalent Population of Metabolic Acidosis in Spain
    • 9.4.2. Total Diagnosed Population of Metabolic Acidosis in Spain
    • 9.4.3. Total Treated Population of Metabolic Acidosis in Spain
  • 9.5. The United Kingdom
    • 9.5.1. Total Prevalent Population of Metabolic Acidosis in the United Kingdom
    • 9.5.2. Total Diagnosed Population of Metabolic Acidosis in the United Kingdom
    • 9.5.3. Total Treated Population of Metabolic Acidosis in the United Kingdom
  • 9.6. Japan Epidemiology
    • 9.6.1. Total Prevalent Population of Metabolic Acidosis in Japan
    • 9.6.2. Total Diagnosed Population of Metabolic Acidosis in Japan
    • 9.6.3. Total Treated Population of Metabolic Acidosis in Japan
  • 9.7. Brazil Epidemiology
    • 9.7.1. Total Prevalent Population of Metabolic Acidosis in Brazil
    • 9.7.2. Total Diagnosed Population of Metabolic Acidosis in Brazil
    • 9.7.3. Total Treated Population of Metabolic Acidosis in Brazil
  • 9.8. China Epidemiology
    • 9.8.1. Total Prevalent Population of Metabolic Acidosis in China
    • 9.8.2. Total Diagnosed Population of Metabolic Acidosis in China
    • 9.8.3. Total Treated Population of Metabolic Acidosis in China
  • 9.9. Mexico Epidemiology
    • 9.9.1. Total Prevalent Population of Metabolic Acidosis in Mexico
    • 9.9.2. Total Diagnosed Population of Metabolic Acidosis in Mexico
    • 9.9.3. Total Treated Population of Metabolic Acidosis in Mexico

10. Unmet Needs

11. Patient Journey of Metabolic Acidosis

12. KOL Views

13. Appendix

  • 13.1. Bibliography
  • 13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1: Summary of Metabolic Acidosis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total Prevalence of CKD patients in the 10EM (2017-2030)
  • Table 3: Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM (2017-2030)
  • Table 4: Total Diagnosed Population of Metabolic Acidosis in the 10EM (2017-2030)
  • Table 5: Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM (2017-2030)
  • Table 6: Total Treated Population of Metabolic Acidosis in the 10EM (2017-2030)
  • Table 7: Total Prevalent Population of Metabolic Acidosis in the United States (2017-2030)
  • Table 8: Total Diagnosed Population of Metabolic Acidosis in the United States (2017-2030)
  • Table 9: Total Treated Population of Metabolic Acidosis in the United States (2017-2030)
  • Table 10: Total Prevalent Population of Metabolic Acidosis in Germany (2017-2030)
  • Table 11: Total Diagnosed Population of Metabolic Acidosis in Germany (2017-2030)
  • Table 12: Total Treated Population of Metabolic Acidosis in Germany (2017-2030)
  • Table 13: Total Prevalent Population of Metabolic Acidosis in France (2017-2030)
  • Table 14: Total Diagnosed Population of Metabolic Acidosis in France (2017-2030)
  • Table 15: Total Treated Population of Metabolic Acidosis in France (2017-2030)
  • Table 16: Total Prevalent Population of Metabolic Acidosis in Italy (2017-2030)
  • Table 17: Total Diagnosed Population of Metabolic Acidosis in Italy (2017-2030)
  • Table 18: Total Treated Population of Metabolic Acidosis in Italy (2017-2030)
  • Table 19: Total Prevalent Population of Metabolic Acidosis in Spain (2017-2030)
  • Table 20: Total Diagnosed Population of Metabolic Acidosis in Spain (2017-2030)
  • Table 21: Total Treated Population of Metabolic Acidosis in Spain (2017-2030)
  • Table 22: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017-2030)
  • Table 23: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017-2030)
  • Table 24: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017-2030)
  • Table 25: Total Prevalent Population of Metabolic Acidosis in Japan (2017-2030)
  • Table 26: Total Diagnosed Population of Metabolic Acidosis in Japan (2017-2030)
  • Table 27: Total Treated Population of Metabolic Acidosis in Japan (2017-2030)
  • Table 28: Total Prevalent Population of Metabolic Acidosis in Brazil (2017-2030)
  • Table 29: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017-2030)
  • Table 30: Total Treated Population of Metabolic Acidosis in Brazil (2017-2030)
  • Table 31: Total Prevalent Population of Metabolic Acidosis in China (2017-2030)
  • Table 32: Total Diagnosed Population of Metabolic Acidosis in China (2017-2030)
  • Table 33: Total Treated Population of Metabolic Acidosis in China (2017-2030)
  • Table 34: Total Prevalent Population of Metabolic Acidosis in Mexico (2017-2030)
  • Table 35: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017-2030)
  • Table 36: Total Treated Population of Metabolic Acidosis in Mexico (2017-2030)
  • Table 37: Commonly Prescribed Alkalinizing Agents, Dosages, and Considerations
  • Table 38: Recommendation according to the GRADE methodology
  • Table 39: Summary of recommendations

List of Figures

  • Figure 1: Mechanisms of acid-mediated tubule interstitial fibrosis in chronic kidney disease (CKD)
  • Figure 2: Algorithm recommended by the experts for etiological diagnosis of metabolic acidemia metabolic acidosis
  • Figure 3: Management of chronic metabolic acidosis (MA) in chronic kidney disease using sodium bicarbonate (NaHCO3)
  • Figure 4: Total Prevalence of CKD patients in the 10EM (2017-2030)
  • Figure 5: Total Prevalence of Metabolic Acidosis in CKD patients of the 10EM (2017-2030)
  • Figure 6: Total Diagnosed Population of Metabolic Acidosis in the 10EM (2017-2030)
  • Figure 7: Gender-Specific diagnosed cases of Metabolic Acidosis in the 10 EM (2017-2030)
  • Figure 8: Total Treated Population of Metabolic Acidosis in the 10EM (2017-2030)
  • Figure 9: Total Prevalent Population of Metabolic Acidosis in the United States (2017-2030)
  • Figure 10: Total Diagnosed Population of Metabolic Acidosis in the United States (2017-2030)
  • Figure 11: Total Treated Population of Metabolic Acidosis in the United States (2017-2030)
  • Figure 12: Total Prevalent Population of Metabolic Acidosis in Germany (2017-2030)
  • Figure 13: Total Diagnosed Population of Metabolic Acidosis in Germany (2017-2030)
  • Figure 14: Total Treated Population of Metabolic Acidosis in Germany (2017-2030)
  • Figure 15: Total Prevalent Population of Metabolic Acidosis in France (2017-2030)
  • Figure 16: Total Diagnosed Population of Metabolic Acidosis in France (2017-2030)
  • Figure 17: Total Treated Population of Metabolic Acidosis in France (2017-2030)
  • Figure 18: Total Prevalent Population of Metabolic Acidosis in Italy (2017-2030)
  • Figure 19: Total Diagnosed Population of Metabolic Acidosis in Italy (2017-2030)
  • Figure 20: Total Treated Population of Metabolic Acidosis in Italy (2017-2030)
  • Figure 21: Total Prevalent Population of Metabolic Acidosis in Spain (2017-2030)
  • Figure 22: Total Diagnosed Population of Metabolic Acidosis in Spain (2017-2030)
  • Figure 23: Total Treated Population of Metabolic Acidosis in Spain (2017-2030)
  • Figure 24: Total Prevalent Population of Metabolic Acidosis in the United Kingdom (2017-2030)
  • Figure 25: Total Diagnosed Population of Metabolic Acidosis in the United Kingdom (2017-2030)
  • Figure 26: Total Treated Population of Metabolic Acidosis in the United Kingdom (2017-2030)
  • Figure 27: Total Prevalent Population of Metabolic Acidosis in Japan (2017-2030)
  • Figure 28: Total Diagnosed Population of Metabolic Acidosis in Japan (2017-2030)
  • Figure 29: Total Treated Population of Metabolic Acidosis in Japan (2017-2030)
  • Figure 30: Total Prevalent Population of Metabolic Acidosis in Brazil (2017-2030)
  • Figure 31: Total Diagnosed Population of Metabolic Acidosis in Brazil (2017-2030)
  • Figure 32: Total Treated Population of Metabolic Acidosis in Brazil (2017-2030)
  • Figure 33: Total Prevalent Population of Metabolic Acidosis in China (2017-2030)
  • Figure 34: Total Diagnosed Population of Metabolic Acidosis in China (2017-2030)
  • Figure 35: Total Treated Population of Metabolic Acidosis in China (2017-2030)
  • Figure 36: Total Prevalent Population of Metabolic Acidosis in Mexico (2017-2030)
  • Figure 37: Total Diagnosed Population of Metabolic Acidosis in Mexico (2017-2030)
  • Figure 38: Total Treated Population of Metabolic Acidosis in Mexico (2017-2030)
  • Figure 39: Adverse effects of acute metabolic acidosis
  • Figure 40: Adverse effects of chronic metabolic acidosis